Glass Pharms has at this time introduced a brand new provide deal set to see a brand new line of inexpensive, solely UK-produced merchandise enter the market.
Three new additions to the ‘EcoCann Entry’ vary, derived from Glass Pharms’ sustainably grown flower, will now be prescribed by CB1 Pharmacy and manufactured by Xeal Pharma.
The merchandise are designed to offer a constant and budget-friendly choice for UK sufferers, with costs set at underneath £6 per gram, following a profitable gentle launch and several other months of collaboration between the 2 firms.
Glass Pharms’ Head of Exterior Relations, Mark Heley, instructed Enterprise of Hashish: “We had already established a profitable partnership with CB1, which has already been prescribing Glass Pharms’ livery flower.
“We began serious about the best way to meet our shared objectives. CB1 is a fast-growing pharmacy with a mission to offer inexpensive entry to medical hashish within the UK, and that was a key consideration for us.”
He defined that, in conversations with sufferers and clinicians, ‘value level got here up time and again’. As such, this new partnership is aimed toward ‘discovering a solution to serve sufferers who want medical hashish on a funds with out compromising on high quality’.
“We’re listening to what sufferers and clinicians are asking for. And for lots of them, it’s a dependable, inexpensive choice that meets medical requirements.”
The three new merchandise are produced from strains that ‘embody attention-grabbing cultivars’, however don’t meet the requirements required for Glass Pharms’ core, extra premium-priced product line in areas like stability or year-round availability.
Simplifying product alternative
In accordance with Prohibition Companions’ newest knowledge, over 500 separate merchandise are actually obtainable to UK sufferers, a degree of alternative many new sufferers can discover intimidating.
In contrast to conventional medical hashish choices that always concentrate on particular cultivars, or strains with distinctive genetics, EcoCann Entry is structured round broader hashish phenotypes: Sativa, Indica and Balanced Hybrid.
These classes, whereas loosely outlined, are generally utilized by clinicians and sufferers to tell apart between ‘daytime’ and ‘nighttime’ results.
“There’s solely a portion of the market that’s hyper-focused on Californian genetics and cultivar names,” Heley defined. “Lots of people need good, constant entry. That’s what that is.”
Every product within the vary will fall into one of many three phenotype classes, permitting prescribers to keep up continuity for sufferers at the same time as particular cultivars change over time. Cultivar particulars will nonetheless be listed for transparency.
For daytime use, Chemstar (SA-T19-CHS) presents a sativa-dominant profile with 19% THC, whereas the balanced hybrid choice, Gelato 33 (BH-T15), options 15% THC and a terpene mix of caryophyllene, limonene, and myrcene, whereas its nighttime cultivar, Motorbreath (IN–T19), presents strong indica-leaning profile with 19% THC.
“We’ll at all times provide a daytime choice, a nighttime choice, and a day/night time (balanced) choice, that maps roughly onto the standard hashish phenotype mannequin—sativa, indica, and hybrid,” Heley continued.
Glass Pharms CEO James Duckenfield added that whereas phenotype classification is ‘not a precise science,’ it stays a ‘helpful approach of figuring out the final indication of a cannabis-based drugs.’
Rooted within the UK
CB1 Medical, the launch accomplice for the vary, operates a big NHS-linked apply in Leicester and types itself because the ‘UK’s most inexpensive medical hashish clinic.’ Founder Professor Rishabh Prasad mentioned the partnership with Glass Pharms would enhance each alternative and accessibility for sufferers.
“I’ve seen Glass Pharms myself,” added CB1 Pharmacy’s Superintendent Pharmacist Irfan Abdulla. “They use essentially the most strong processes to keep up the very best high quality drugs.”
The brand new line additionally appeals to clinicians looking for prescribing stability in a market typically suffering from provide inconsistency.
For Glass Pharms, the EcoCann Entry venture is an extra extension of its UK-first ethos.
The corporate, which grows medical hashish in a 2.4-hectare greenhouse within the West of England, grew to become the primary UK cultivator since medical hashish was legalised in 2018 to ship domestically grown product to sufferers final 12 months.
